5 completed, 5 terminated, 4 recruiting, 4 unknown. 24 Phase 2, 4 Phase 3.
Follow Induction Chemotherapy: new trials by email Literature Review of Induction Chemotherapy trials Research Report on Induction Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma Immunotherapy, Induction chemotherapy, D2 radical gastrectomy - Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 15 | 2026-01-31 | 2026-01-07 |
| Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Second Affiliated Hospital of Zunyi Medical University | 92 | 2026-01-01 | 2026-04-30 |
| PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation - Esophageal Cancer, Oesophageal Cancer | Phase 2 | Recruiting | Medical College of Wisconsin | 50 | 2025-06-17 | 2026-07-28 |
| Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia Blinatumomab, Induction Chemotherapy, Hyper-CVAD - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 101 | 2025-04-01 | 2026-05-04 |
| Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT Toripalimab, Induction chemotherapy and concurrent chemoradiation - Nasopharyngeal Cancer | Phase 2 | Recruiting | Fudan University | 198 | 2022-07-02 | 2022-11-29 |
| Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer induction chemotherapy and immunotherapy - ESCC | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 44 | 2022-01-01 | 2025-06-11 |
| Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma Induction chemotherapy, Carbon-ion radiotherapy, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Shanghai Proton and Heavy Ion Center | 146 | 2021-01-19 | 2022-04-29 |
| Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma Anlotinib hydrochloride, induction chemotherapy, concurrent chemoradiation - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Zhejiang Cancer Hospital | 37 | 2021-01-01 | 2022-02-10 |
| Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer induction chemotherapy, surgery, chemoradiotherapy - Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 100 | 2020-03-01 | 2020-03-05 |
| International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma Radiotherapy without Carboplatin, Reduced-intensity maintenance chemotherapy, Radiotherapy with Carboplatin - Brain Tumors | Phase 2 / Phase 3 | Active not recruiting | Universitätsklinikum Hamburg-Eppendorf | 360 | 2014-06-01 | 2025-12-04 |
| Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study Chrono-chemotherapy pump:Melodie, Routine intravenous drip, induction chemotherapy - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Feng Jing | 160 | 2014-05-01 | 2014-07-11 |
| Treating NSCLC Minimal Stage IV With Curative Intent Induction chemotherapy and concurrent radiation, Consolidation: Radiation therapy to metastatic sites - Non-small Cell Lung Cancer | Phase 2 | Terminated | Leo W. Jenkins Cancer Center | 14 | 2013-06-01 | 2019-08-21 |
| Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Induction Chemotherapy, Consolidation Chemotherapy, Autologous Stem Cell Transplantation - Acute Myeloid Leukemia, Myeloproliferative Neoplasms | Phase 2 | Completed | Hospital Israelita Albert Einstein | 455 | 2012-10-01 | 2016-11-08 |
| A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer Pertuzumab, Trastuzumab, Aromatase Inhibitor - Breast Cancer | Phase 2 | Completed | Hoffmann-La Roche | 258 | 2012-02-17 | 2020-10-28 |
| A Study of Tongue Conservation Surgery for Oral Tongue Cancer Induction chemotherapy, Tongue conservation surgery, postoperative CCRT - Tongue Cancer, Chemotherapy Effect | Phase 2 | Terminated | Taipei Veterans General Hospital, Taiwan | 23 | 2011-07-18 | 2017-05-30 |
| A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects decitabine Induction Chemotherapy, Induction Chemotherapy - Acute Myelogenous Leukemia (AML) | Phase 2 | Withdrawn | Eisai Inc. | 2010-06-01 | 2015-04-13 | |
| Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy - Brain and Central Nervous System Tumors | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 293 | 2007-12-17 | 2026-10-16 |
| Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML) induction chemotherapy (fludarabine, cytarabine, idarubicin) - Acute Myeloid Leukemia | Phase 2 | Completed | Seoul National University Hospital | 108 | 2007-06-01 | 2010-11-24 |
Showing 20 of 24. Sign in to see all of them.
Leukemia, Myeloid, Acute (5) · Nasopharyngeal Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Myelodysplastic Syndromes (2) · Squamous Cell Carcinoma of Head and Neck (2) · Anemia, Refractory, with Excess of Blasts (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Squamous Cell (1) · Central Nervous System Neoplasms (1) · Choroid Plexus Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Esophagitis (1)
First Affiliated Hospital of Zhejiang University (2) · Centre Hospitalier Universitaire de Saint Etienne (1) · Eisai Inc. (1) · Feng Jing (1) · Fudan University (1) · Genmab (1) · Hoffmann-La Roche (1) · Hospital Israelita Albert Einstein (1) · Leo W. Jenkins Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · Peking Union Medical College Hospital (1) · SWOG Cancer Research Network (1) · Second Affiliated Hospital of Zunyi Medical University (1) · Seoul National University Hospital (1)
China (9) · United States (7) · France (4) · United Kingdom (3) · Belgium (2) · Brazil (2) · India (2) · Italy (2) · Netherlands (2) · Spain (2) · Australia (1) · Austria (1) · Czechia (1) · Denmark (1) · Germany (1)
Amar Gajjar, MD (1) · Chao-su Hu, M.D. (1) · Chunmei Bai (1) · Fabio P Santos, MD (1) · Francois Doz, Prof. Dr. (1) · Inho Kim (1) · Jeffrey Miller, MD (1) · Jiade J Lu, MD (1) · Lei Zhou, Master (1) · Lindsay Puckett, MD (1) · Nelson Hamerschlak, MD, PhD (1) · Paul Walker, MD, PhD (1) · Peter Tarassoff, MD (1)
PMID 15625363, PMID 17579184, PMID 23077109, PMID 29778738, PMID 30106636, PMID 33502920, PMID 33945291, PMID 38205914, PMID 40967259
R01CA154619 (1), U10CA032102 (1)